This handout is for thrombocytopenia symptom-triage (ed-primary; ttp/dic/hit/itp/hellp route + outpatient chronic). Your care team identified this based on: isolated thrombocytopenia (plt <100k, normal hgb + wbc, normal smear except large platelets) + no obvious secondary cause — primary itp; route heme.itp.core.v1 (acute) or heme.itp.chronic.v1 (>12 mo); first-line prednisone 1 mg/kg or dexamethasone 40 mg × 4 d; rescue ivig/anti-d + platelets if severe bleed (itp ash 2019 pmid 31585375).
Other reasons your team may use this plan: microangiopathic hemolytic anemia (schistocytes >2/hpf) + thrombocytopenia + ± neuro/renal/fever + plasmic score ≥6 + adamts13 <10% — ttp; stat plasma exchange (plex) — do not delay for adamts13; route heme.ttp.core.v1 (ttp isth 2017 pmid 31135051 verify); 4ts score ≥4-8 (thrombocytopenia 30-50% drop, timing 5-10d after heparin, thrombosis new venous/arterial, other cause excluded) + hit antibody (pf4 elisa) + functional confirmatory (sra) — heparin-induced thrombocytopenia; stop all heparin + alternative anticoag (fondaparinux/argatroban/bivalirudin) — avoid platelet transfusion (hit ash 2018 pmid 28811261 verify; 4ts pmid 23613659 verify); thrombocytopenia + prolonged pt/ptt + fibrinogen low <100 + d-dimer very high + clinical (sepsis, ob, trauma, apl, snake) + isth dic score ≥5 — dic; treat underlying + supportive (cryo for fibrinogen <100, ffp for inr >1.5, plt for plt <30k if bleeding); route heme.dic.v1 (dic isth 2018 pmid 26966077 verify).
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Hematology for ITP chronic + HIT + TTP relapse + hereditary. ID for HIV/HCV/HBV viral suppression. Rheumatology for SLE flares. Obstetrics for HELLP postpartum + future pregnancy planning. Avoid future heparin exposure for HIT (lifelong); use fondaparinux/DOAC instead. ITP — vaccinations for splenectomy candidates; eltrombopag/romiplostim long-term monitoring (bone marrow fibrosis). Recurrence prevention.
Guideline: 2019 ITP ASH + 2017 TTP ISTH + 2018 HIT ASH + 2018 DIC ISTH + HERCULES caplacizumab + ITP Provan international consensus